» Articles » PMID: 30826887

Pattern of Metastatic Deposit in Recurrent Prostate Cancer: a Whole-body MRI-based Assessment of Lesion Distribution and Effect of Primary Treatment

Overview
Journal World J Urol
Specialty Urology
Date 2019 Mar 4
PMID 30826887
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: It is generally accepted that when metastases develop in a patient with biochemical recurrence of prostate cancer (PCa), they follow a centrifuge pattern of seeding from the pelvis and that most patients enter the disease as oligometastatic. In this study, we used whole-body magnetic resonance imaging (WB-MRI) to assess the anatomical distribution of oligo- and polymetastatic disease and the impact of the initial treatment on this distribution in patients.

Materials And Methods: WB-MRI examinations of patients with a rising prostate-specific antigen (PSA) after radical treatment by surgery or/and radiotherapy were analyzed for disease recurrence. The patients were separated into three groups, based on the primary treatment: patients treated by radical prostatectomy without radiotherapy and with/without lymph node dissection (RP), patients treated only by radiotherapy or hormono-radiotherapy (RT) and patients treated with radical prostatectomy and adjuvant or salvage radiotherapy (RP + RT). Patients with ≤ 5 bone or/and node metastases were considered oligometastatic. Regional distributions of bone and lymph nodes metastases were reported using anatomical diagrams. Univariate and multivariable logistic regressions were performed to identify prognostic factors of relapse.

Results: The primary treatment (RP, RT, RP + RT), Gleason score, PSA at relapse, time between first diagnosis and recurrence did not influence the metastatic status (oligo vs. polymetastatic). Oligometastatic patients showed different distribution of bone metastases compared to the polymetastatic ones and the distribution of the oligometastatic disease was not influenced by the primary treatment.

Conclusions: In this WB-MRI-based study, there was no evidence that the primary treatment influenced the metastatic status of the patient or the distribution of the oligometastatic disease.

Citing Articles

Simple immobilization for stereotactic radiotherapy aimed at pelvic metastases.

Janssen J, Brouwer C, Staal F, van Herpt H, Both S, Langendijk J Phys Imaging Radiat Oncol. 2023; 27:100460.

PMID: 37435559 PMC: 10331836. DOI: 10.1016/j.phro.2023.100460.


PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer.

Combes A, Palma C, Calopedos R, Wen L, Woo H, Fulham M Diagnostics (Basel). 2022; 12(11).

PMID: 36359439 PMC: 9689635. DOI: 10.3390/diagnostics12112594.


Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.

Sutera P, Van der Eecken K, Kishan A, Hamid A, Grist E, Attard G Prostate Cancer Prostatic Dis. 2022; 25(4):713-719.

PMID: 35013522 PMC: 9310084. DOI: 10.1038/s41391-021-00484-4.


Whole-Body MRI vs. PET/CT for the Detection of Bone Metastases in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.

Zhan Y, Zhang G, Li M, Zhou X Front Oncol. 2021; 11:633833.

PMID: 34017680 PMC: 8130579. DOI: 10.3389/fonc.2021.633833.


Developments in oligometastatic hormone-sensitive prostate cancer.

Tran P, Ost P World J Urol. 2019; 37(12):2545-2547.

PMID: 31705198 DOI: 10.1007/s00345-019-03009-w.

References
1.
Tamoto E, Tada M, Murakawa K, Takada M, Shindo G, Teramoto K . Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer. Clin Cancer Res. 2004; 10(11):3629-38. DOI: 10.1158/1078-0432.CCR-04-0048. View

2.
Padhani A, Lecouvet F, Tunariu N, Koh D, De Keyzer F, Collins D . Rationale for Modernising Imaging in Advanced Prostate Cancer. Eur Urol Focus. 2017; 3(2-3):223-239. DOI: 10.1016/j.euf.2016.06.018. View

3.
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

4.
Rischke H, Schultze-Seemann W, Wieser G, Kronig M, Drendel V, Stegmaier P . Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol. 2014; 191(4):310-20. DOI: 10.1007/s00066-014-0763-5. View

5.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View